These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 18188561)

  • 1. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
    Beachy SH; Repasky EA
    Cancer Immunol Immunother; 2008 Jun; 57(6):759-75. PubMed ID: 18188561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP; Bonavida B
    Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
    Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.
    Linder S; Havelka AM; Ueno T; Shoshan MC
    Cancer Lett; 2004 Oct; 214(1):1-9. PubMed ID: 15331168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of circulating nucleosomes in cancer.
    Holdenrieder S; Nagel D; Schalhorn A; Heinemann V; Wilkowski R; von Pawel J; Raith H; Feldmann K; Kremer AE; Müller S; Geiger S; Hamann GF; Seidel D; Stieber P
    Ann N Y Acad Sci; 2008 Aug; 1137():180-9. PubMed ID: 18837945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 11. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF; Erff M; Ashkenazi A
    Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
    Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
    Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
    J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring.
    Bidart JM; Thuillier F; Augereau C; Chalas J; Daver A; Jacob N; Labrousse F; Voitot H
    Clin Chem; 1999 Oct; 45(10):1695-707. PubMed ID: 10508114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.
    Wu M; Zhang Y; Zhang Y; Liu Y; Wu M; Ye Z
    Radiol Imaging Cancer; 2019 Nov; 1(2):e190031. PubMed ID: 33778682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy.
    Stoetzer OJ; Wittwer C; Lehner J; Fahmueller YN; Kohles N; Fersching DM; Leszinski G; Roessner J; Holdenrieder S
    Expert Opin Biol Ther; 2012 Jun; 12 Suppl 1():S217-24. PubMed ID: 22620489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.
    Zhu L; Staley C; Kooby D; El-Rays B; Mao H; Yang L
    Cancer Lett; 2017 Mar; 388():139-148. PubMed ID: 27916607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy control in oncology by circulating nucleosomes.
    Holdenrieder S; Stieber P
    Ann N Y Acad Sci; 2004 Jun; 1022():211-6. PubMed ID: 15251962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
    Hermisson M; Weller M
    Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.